Current drug options for raising HDL cholesterol

Current Treatment Options in Cardiovascular Medicine

Volumn 7, Issue 1, 2005, Pages 15-23

  Dunbar, Richard L ^a   Rader, Daniel J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANABOLIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BILE ACID SEQUESTRANT; CIPROFIBRATE; CLARITHROMYCIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; ERYTHROMYCIN; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOFIBRA; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEFAZODONE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ABDOMINAL PAIN; ACANTHOSIS NIGRICANS; AGE; AMBLYOPIA; ANEMIA; ARTHRALGIA; BACKACHE; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DISORDERS OF CHOLESTEROL METABOLISM; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG TARGETING; DYSLIPIDEMIA; DYSPEPSIA; EVIDENCE BASED MEDICINE; EXERCISE; FATIGUE; FLATULENCE; FLUSHING; FOOD DRUG INTERACTION; FOOD INTAKE; HEADACHE; HEALTH PROGRAM; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPOTENSION; INDIVIDUALIZATION; LEUKOPENIA; LIFESTYLE; LIVER DYSFUNCTION; LIVER TOXICITY; MEDICAL DECISION MAKING; MUSCLE CRAMP; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PEPTIC ULCER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRURITUS; RASH; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; THROMBOCYTOPENIA; URTICARIA; VASODILATATION; VOMITING;

EID: 21244497302     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-005-0002-6     Document Type: Review

References (38)

1. Barter P, Kastelein J, Nunn A, Hobbs R: High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003, 168:195-211.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [no authors listed]. Circulation 2002, 106:3143-3421.
3. Rader DJ: High-density lipoproteins and atherosclerosis. Am J Cardiol 2002, 90:62i-70i.
4. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
5. Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591.
6. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
7. Sacks FM: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002, 90:139-143.
8. Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002, 40:1366-1374.
9. Pearson TA, Blair SN, Daniels SR, et al.: AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002, 106:388-391.
10. De Backer G, Ambrosioni E, Borch-Johnsen K, et al.: European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003, 24:1601-1610.
11. Genest J, Frohlich J, Fodor G, McPherson R: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003, 169:921-924.
12. Mosca L, Appel LJ, Benjamin EJ, et al.: Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004, 109:672-693.
13. Haffner SM, American Diabetes Association: Dyslipidemia management in adults with diabetes. Diabetes Care 2004, 27:68S-71S.
14. Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004, 110:588-636.
15. Chapman MJ, Assmann G, Fruchart JC, et al.: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004, 20:1253-1268.
16. Thompson PD, Buchner D, Pina IL, et al.: Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003, 107:3109-3116.
17. Couillard C, Despres JP, Lamarche B, et al.: Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001, 21:1226-1232.
18. Durstine JL, Thompson PD: Exercise in the treatment of lipid disorders. Cardiol Clin 2001, 19:471-488.
19. Ellison RC, Zhang Y, Qureshi MM, et al.: Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J 2004, 147:529-535.
20. Szapary PO, Rader DJ: The triglyceride-high-density lipoprotein axis: an important target of therapy? Am Heart J 2004, 148:211-221.
21. Insull W Jr, McGovern ME, Schrott H, et al.: Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004, 164:1121-1127.
22. McKenney J: Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm 2003, 60:995-1005.
23. Bays HE, Stein EA: Pharmacotherapy for dyslipidaemia - current therapies and future agents. Expert Opin Pharmacother 2003, 4:1901-1938.
24. Elam MB, Hunninghake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284:1263-1270.
25. Gotto AM Jr, Brinton EA: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004, 43:717-724.
26. Rubic T, Trottmann M, Lorenz RL: Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004, 67:411-419.
27. Rader DJ: Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. Am J Cardiol 2003, 91:18E-23E.
28. Grundy S, Vega G, McGovern M, et al.: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 2002, 162:1562-1576.
29. Meyers CD, Carr MC, Park S, Brunzell JD: Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 2003, 139:996-1002.
30. Drug Topics Red Book. Montvale, NJ: Medical Economics Co.; 2003.
31. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators [no authors listed]. Br Heart J 1978, 40:1069-1118.
32. Prueksaritanont T, Zhao JJ, Ma B, et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002, 301:1042-1051.
33. Ballantyne CM, Corsini A, Davidson MH, et al.: Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003, 163:553-564.
34. Fruchart JC, Brewer HB Jr, Leitersdorf E: Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998, 81:912-917.
35. Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(23 suppl 1):III50-III57.
36. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002, 106:1024-1028.
37. Insua A, Massari F, Rodriguez Moncalvo JJ, et al.: Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract 2002, 8:96-101.
38. Vytorin (Ezetimibe/Simvastatin tablets) [package insert]. West Point, PA: Merck & Co.; 2004.